Demand for drugs in Russia may decline significantly in 2016

29 December 2015
moscow-big
Dmitry Azovtsev

The demand for drugs in Russia may decline significantly in 2016, mainly due to the ongoing financial crisis in the country, caused by Western sanctions and the reduction of purchasing power of local population, according to recent predictions of Veronika Skvortsova, Russia’s Minister of Health, reports The Pharma Letter’s local correspondent.

It is predicted that the drop in demand will be observed in all segments of the market, and mainly low- and middle-priced drugs. The unfavorable economic situation in Russia will prevent implementation of state plans for the replacement of imports in the domestic pharmaceutical market by 2020.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical